nimodipine has been researched along with Meniere Disease in 4 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
Meniere Disease: A disease of the inner ear (LABYRINTH) that is characterized by fluctuating SENSORINEURAL HEARING LOSS; TINNITUS; episodic VERTIGO; and aural fullness. It is the most common form of endolymphatic hydrops.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Due to its proposed vasoactive and neuroprotective effects, nimodipine may play a role in the treatment of a number of otolaryngic pathologies including VS, Ménière's disease, peripheral vertigo, RLN injury, and facial weakness after maxillofacial surgery." | 4.98 | Nimodipine for the treatment of otolaryngic indications. ( Levy, ZD; Shafeeq, H; Sin, JH, 2018) |
| " A total of 113 medical records were analysed; 53 patients received betahistine-dihydrochloride at on-label dosage (32 mg die) for six months, and 60 patients were treated with the same regimen and nimodipine (40 mg die) as an add-therapy during the same period." | 1.38 | Effect of a fixed combination of nimodipine and betahistine versus betahistine as monotherapy in the long-term treatment of Ménière's disease: a 10-year experience. ( Aggazzotti Cavazza, E; Alicandri Ciufelli, M; Barillari, MR; Genovese, E; Monzani, D; Neri, V; Presutti, L, 2012) |
| "Nimodipine is a highly lipophilic, centrally acting calcium channel blocker." | 1.29 | Use of nimodipine in the medical treatment of Menière's disease: clinical experience. ( Hirsch, BE; Kamerer, DB; Lassen, LF, 1996) |
| "12 patients showed sudden deafness with a history of one day up to more than 20 years." | 1.27 | [Nimodipine (Bay e 9736) a new therapy concept in diseases of the inner ear?]. ( Theopold, HM, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sin, JH | 1 |
| Shafeeq, H | 1 |
| Levy, ZD | 1 |
| Monzani, D | 1 |
| Barillari, MR | 1 |
| Alicandri Ciufelli, M | 1 |
| Aggazzotti Cavazza, E | 1 |
| Neri, V | 1 |
| Presutti, L | 1 |
| Genovese, E | 1 |
| Lassen, LF | 1 |
| Hirsch, BE | 1 |
| Kamerer, DB | 1 |
| Theopold, HM | 1 |
1 review available for nimodipine and Meniere Disease
| Article | Year |
|---|---|
Nimodipine for the treatment of otolaryngic indications.
Topics: Calcium Channel Blockers; Humans; Meniere Disease; Neuroprotective Agents; Nimodipine; Otorhinolaryn | 2018 |
3 other studies available for nimodipine and Meniere Disease
| Article | Year |
|---|---|
Effect of a fixed combination of nimodipine and betahistine versus betahistine as monotherapy in the long-term treatment of Ménière's disease: a 10-year experience.
Topics: Adult; Betahistine; Drug Therapy, Combination; Female; Humans; Male; Meniere Disease; Middle Aged; N | 2012 |
Use of nimodipine in the medical treatment of Menière's disease: clinical experience.
Topics: Calcium Channel Blockers; Female; Hair Cells, Auditory; Humans; Male; Meniere Disease; Nimodipine; R | 1996 |
[Nimodipine (Bay e 9736) a new therapy concept in diseases of the inner ear?].
Topics: Adult; Aged; Auditory Threshold; Calcium Channel Blockers; Female; Hearing Loss, Noise-Induced; Hear | 1985 |